Proposed medical marijuana dispensary sold for $950K; contracting work begins – Milton Daily Standard


SHAMOKIN — The former bank building at 520 N. Shamokin St., which was scheduled to open last June as a medical marijuana dispensary before Harvest of North Central PA LLC later relinquished its permits, has been sold for $950,000 to another medical marijuana dispensary known as PharmaCann LLC.

According to records in the Northumberland County Assessor’s Office, the sale was completed March 3 between Harvest DCP and NLCP LLC. Third-party inspector permits have been issued to PharmaCann and construction work began at the property Monday morning.

PharmaCann, which is headquartered in Chicago, Illinois, initially planned to locate at 235 W. Spruce St., Shamokin, but later sought a new location.

According to PharmaCann’s website, the company was founded in 2014. It is one of the country’s largest vertically integrated cannabis companies, providing safe, reliable, top-quality cannabis products to improve people’s lives.

PharmaCann’s goal is to increase sustainable access to cannabis by offering effective, affordable and trusted products and services.

The company is licensed in eight states to grow, process and/or dispense medical cannabis products for adult and pediatric patients, as well as for responsible adult use.

Its dispensaries operate under the brand Verilife and are designed to help people feel better and get more enjoyment out of life by becoming comfortable with the safe, informed use of quality cannabis.

The company is constantly researching and developing new forms and formulations of cannabinoid-based treatments to improve people’s well-being.

Shamokin Mayor John Brown said he’s optimistic the new owner of the building will be successful in operating a medical marijuana facility after the city experienced a “rollercoaster ride” with Harvest.

“We were thrilled when Harvest bought the building and put in

Read More Here...

Share on facebook
Share on twitter
Share on reddit
Share on pinterest
Share on email

Leave a comment

Your email address will not be published. Required fields are marked *